Simcere receives approval for SIM0686 clinical trial in China

Simcere Pharmaceutical Group Limited (HKEX: 2096) announced that it has received clinical trial approval from the National Medical Products Administration of China for SIM0686, an FGFR2b Antibody-Drug Conjugate (ADC). SIM0686, independently developed by the Group, is an anti-tumor drug candidate intended for commencing clinical trials for advanced solid tumors. SIM0686 targets FGFR2b, a transmembrane tyrosine kinase receptor of fibroblast growth factor (FGF), and is intended for the treatment of advanced malignant tumors like gastric cancer and lung cancer. The announcement highlights Simcere's focus on innovative R&D and its strategic partnerships with research institutions.